On April 16, 2026 Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious diseases, reported two poster presentations will be featured at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17-22 in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations cover data from the ongoing Phase 1 clinical trial of tolododekin alfa, a novel IL-12 anchored immunotherapy, and preclinical data on anchored immunotherapy in combination with HDAC for the treatment of checkpoint-refractory solid tumors. Patients interested in enrolling in the Phase 1 clinical trial at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), may contact the toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615) and/or visit the web site: View Source and/or email [email protected].
Presentation details:
Title: Immune Escape via Myeloid-Derived Suppressor Cells in Solid Tumor Cancer Patients Treated with Anchored IL-12 (Tolododekin Alfa)?
Type: Poster Presentation
Session: First-in-Human Phase 1 Clinical Trials
Date and time: April 20, 2:00-5:00pm PST
Abstract number: CT123
Lead author: Wiem Lassoued, Ph.D., Center for Immuno-oncology, National Cancer Institute
Title: Intratumoral IL-12 in combination with HDAC inhibition overcomes checkpoint-refractory tumors
Type: Poster Presentation
Session: Combination Immunotherapies
Date and time: April 20, 9:00am-12:00pm PST
Abstract number: 1563
Lead author: Ainara Meler, Ph.D., Center for Immuno-oncology, National Cancer Institute
About tolodoken alfa
Tolododekin alfa is an investigational, first-in-class interleukin-12 (IL-12)-anchored immunotherapy. IL-12 is a highly potent proinflammatory cytokine, but its therapeutic use has been limited by toxicity. With Ankyra’s anchoring technology, tolododekin alfa has been shown to deliver and retain high doses of IL-12 in the tumor microenvironment. Early results from an ongoing Phase 1 study show durable retention within tumors, encouraging clinical activity, and a favorable safety profile, with no dose-limiting toxicities across multiple difficult-to-treat solid tumor types. Ankyra is also evaluating tolododekin alfa for the treatment of non-small cell lung cancer and cutaneous squamous cell carcinoma.
(Press release, Ankyra Therapeutics, APR 16, 2026, View Source [SID1234664449])